IsoRay moves Proxcelan plant to WA:
This article was originally published in Clinica
Executive Summary
Manufacturer of Proxcelan brachytherapy seeds IsoRay Medical is set to move production to a new facility in Richland, Washington. The new plant, which will house the company's radioactive and non-radioactive facilities, brings IsoRay's operations to a single location. Production of the company's primary product will be doubled and the company will undergo the development of isotopes for new cancer treatments. Proxcelan is the brand name for cesium-131 seeds designed to treat prostate cancer via low dose radiation. Although the technology has solely been used to treat prostate cancer, it received FDA clearance for the treatment of all malignancies in March 2003.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.